ArticleBMC immunology2025
SIRT5 affects lipid accumulation in cells of a metabolic-associated fatty liver disease model by regulating the succinylation status of HSPD1.
Article in BMC immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic-associated fatty liver disease (MAFLD) is a liver disease characterized by abnormal lipid metabolism. This study investigated the effects of succinylation on hepatocyte steatosis and lipid storage in MAFLD in vitro.
methodsmRNA and protein levels of two desuccinylases (SIRT5 and SIRT7) and three succinylases (KAT2A, KAT3B, and CPT1A) were evaluated in blood samples from MAFLD patients. Exposure of HepG2 and Huh7 cells to free fatty acids (FFA) was established to mimic MAFLD in vitro. Triglyceride (TG) content, total cholesterol (TC) content, and lipid accumulation were combined to evaluate lipid metabolism. HSPD1 protein was pulled-down using immunoprecipitation (IP). Co-immunoprecipitation (co-IP) combined with immunofluorescence was used to verify the interaction between SIRT5 and HSPD1.
resultsSIRT5 was prominently down-regulated in blood samples of patients with MAFLD. FFA exposure induced lipid metabolism dysfunction by increasing TC, TG levels, and the number of Oil Red O and BODIPY-stained lipid droplets. Overexpression of SIRT5 significantly attenuated the effects of FFA on lipid metabolism. HSPD1 was found to interact with SIRT5, which mediated HSPD1 desuccinylation and accelerated its protein degradation. Overexpression of HSPD1 sharply reversed the protective effects of elevated SIRT5 on cellular steatosis in HepG2 and Huh7 cells. SIRT5 directly interacted with HSPD1, and elevated SIRT5 levels reduced HSPD1 protein stability through desuccinylation modification.
conclusionSIRT5-mediated desuccinylation of HSPD1 protects against hepatic steatosis in MAFLD model cells, suggesting that targeting SIRT5 and HSPD1 may represent a novel therapeutic strategy for preventing and treating MAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.